Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…Abstract Number: 1181 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine: Do We All See Eye to Eye? a Single-Site Analysis of Hydroxychloroquine Dosing Compared to 2016 American Academy of Ophthalmology Guidelines
Background/Purpose: Hydroxychloroquine is universally recommended to treat patients with SLE, stressing the importance of appropriate dosing. The 2016 American Academy of Ophthalmology (AAO) guidelines recommend…Abstract Number: 1382 • 2018 ACR/ARHP Annual Meeting
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Background/Purpose: QuantiFERON-TB Gold is commercial interferon-γ release assay used to screen patients for tuberculosis before starting or while on immunosuppressive therapies. Clinical studies on efficacy…Abstract Number: 2628 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and Prednisone Have Different Effects on Antiphospholipid Antibodies in SLE, with Hydroxychloroquine Not Reducing IgA Anticardiolipin
Background/Purpose: Antiphospholipid antibodies in SLE may be changed by treatment, but past studies have been conflicting. We examined the impact of starting or stopping two…Abstract Number: 2631 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Levels Are Significantly Associated with Cardiovascular Risk Factors
Background/Purpose: In studies of SLE patients, the benefits of hydroxychloroquine (HCQ) extend beyond control of disease activity. In particular, HCQ use has decreased multiple cardiovascular…Abstract Number: 2634 • 2018 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for SLE because of its highly favorable risk-benefit ratio. Drug-induced retinopathy is one of very few serious…Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…Abstract Number: 2582 • 2017 ACR/ARHP Annual Meeting
Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus
Compliance and persistence with hydroxychloroquine in patients with systemic lupus erythematosusBackground/Purpose: Lifelong treatment with hydroxychloroquine (HCQ) is now recommended for all patients with systemic lupus…Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…Abstract Number: 755 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort
Background/Purpose: Hydroxychloroquine (HCQ) is recommended for all patients with SLE. While patient reported adherence rates are between 51-64%, blood HCQ level testing may be a…Abstract Number: 1782 • 2015 ACR/ARHP Annual Meeting
a Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan
Background/Purpose: In Japan hydroxychloroquine (HCQ) is still unavailable due to the banning of chloroquine in 1974 following allegations that it caused severe retinopathy. Therefore, a…Abstract Number: 1802 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population
Background/Purpose: Hydroxychloroquine (HCQ) dose adjustment in patients with impaired renal function has been suggested to prevent toxicity. However, evidence to support this practice is scant. …Abstract Number: 1925 • 2014 ACR/ARHP Annual Meeting
Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients
Background/Purpose: Hydroxychloroquine (HCQ) is now recognized as an important treatment of systemic lupus erythematosus (SLE). Blood HCQ levels ([HCQ]) can be quantified by high performance…Abstract Number: 559 • 2013 ACR/ARHP Annual Meeting
Effects Of In Vivo Treatment With Hydroxychloroquine On Endothelial Function In a Murine Model Of Systemic Lupus Erythematosus
Background/Purpose: Antimalarial drugs are a cornerstone of treatment of systemic lupus erythematosus (SLE). It has been suggested that antimalarial drugs may have a protective effect…Abstract Number: 200 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Among Systemic Lupus Erythematosus Patients In An Academic Rheumatology Practice
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay in the current treatment of systemic lupus erythematosus (SLE). HCQ has been shown to reduce the incidence of SLE…